Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GeparOcto: ETC vs PM(Cb) in Early Breast Cancer
NCT02125344Phase 3Completed
- Sponsor
- GBG Forschungs
- Start
- Dec 2014
- Primary completion
- Nov 2016
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of doxorubicin in breast cancer, sponsored by GBG Forschungs. Started Dec 2014; status: completed.
02
Drugs
doxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02125344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02125344.